ClinicalTrials.gg
CompletedNCT03351478SOTA-EMPAUpdated May 11, 2021Results posted

Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin

A Phase 3 interventional study of Sotagliflozin and Empagliflozin in Type 2 Diabetes Mellitus, sponsored by Lexicon Pharmaceuticals. Completed at 160 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-05-11.

Sponsored by Lexicon Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
770
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing sotagliflozin in Diabetes Mellitus, Type 2 — 3 open to participants now, 3 under way, none of them phase 3. sotagliflozin · Diabetes Mellitus, Type 2.

Enrollment
5th of 28
770 · median 208
Started
2017
with 8 others
Phase 3
13 of 28
none open now
Registered
18th of 28
by date
Lead sponsor
17 of 28
Lexicon Pharmaceuticals

Among the 28 studies testing sotagliflozin in Diabetes Mellitus, Type 2, this one is the 5th largest by enrollment, is one of 9 that started in 2017, is one of 13 in phase 3, and was the 18th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 28 studies testing sotagliflozin in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About sotagliflozin

sotagliflozin: first FDA approval 2023 (INPEFA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing sotagliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of the study is to demonstrate the superiority of sotagliflozin versus placebo on hemoglobin A1c (HbA1c) reduction in participants with type 2 diabetes (T2D) who have inadequate glycemic control on a DPP4(i) with or without metformin.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with Type 2 Diabetes on Dipeptidyl peptidase-4 inhibitors(DPP4(i)) with or without metformin at a stable dose for at least 12 weeks prior to Screening Visit. Metformin dose will be ≥1500 mg per day (or maximum tolerated dose [documented]). DPP4(i) dose must be the appropriate dose as per local label.
  • Signed written .

Exclusion criteria

Exclusion criteria:

  • (BMI) ≤20 kg/m\^2 or >45 kg/m\^2 at Screening.
  • Use of any antidiabetic drug other than DPP4 inhibitors and metformin within 12 weeks preceding the Screening Visit.
  • Participants who have previously participated in any clinical trial of sotagliflozin/LX4211.
  • Use of a selective sodium-glucose co-transporter type 2 (SGLT2) inhibitor (e.g., canagliflozin, dapagliflozin, or empagliflozin) within 3 months prior to the screening visit.
  • Participants with severe anemia, severe cardiovascular disease (including congestive heart failure IV), respiratory, hepatic, neurological, psychiatric, or active malignant tumor or other major systemic disease or participants with a short that, according to Investigator, will preclude their safe participation in this study, or will make the implementation of the protocol or interpretation of the study results difficult.
  • Current diagnosis of chronic hepatitis and/or other clinically active liver disease requiring treatment.
  • Participants with to empagliflozin as per local labelling.
  • Participants with contraindication to metformin as per local labelling.
  • \<7.0% or >11.0% at Screening (central laboratory).
  • Fasting plasma glucose >270 mg/dL (>15.0 mmol/L) measured by the central laboratory at Screening (Visit 1), and confirmed by a repeat test (>270 mg/dL [>15.0 mmol/L]) before Randomization.
  • Previous use of any type of insulin for >1 month (except for treatment of gestational diabetes).
  • Pregnant (confirmed by serum pregnancy test at Screening) or breast-feeding women.
  • Women of not willing to use highly effective method(s) of during the study treatment period and follow-up period, or who are unwilling or unable to be tested for pregnancy during the study.
  • Mean of 3 separate blood pressure (BP) measurements >180 mmHg (systolic blood pressure [SBP]) or >100 mmHg (diastolic blood pressure [DBP]).
  • History of the hypertensive crisis resulting in emergency medical care within 12 weeks prior to Screening Visit.
  • Lower extremity complications (such as skin ulcers, infection, osteomyelitis, and gangrene) identified during the Screening period, and still requiring treatment at Randomization.
  • Laboratory findings with the central laboratory tests at Visit 1:
  • (ALT) or aspartate aminotransferase (AST) >3 times the laboratory range (ULN);
  • Total >1.5 times the ULN (except in case of Gilbert's syndrome);
  • Neutrophils \<1 500/mm\^3 (or according to ethnic group) and/or \<100 000/mm\^3;
  • Amylase and/or lipase >3 times the ULN;
  • Participants with renal impairment as defined by the estimated (eGFR) criterion that precludes initiation of empagliflozin as per the approved local label (eg, \<45 mL/min/1.73 m\^2 in US; \<60 mL/min/1.73 m\^2 in EU).
  • Secondary hypertension of any etiology (eg, renovascular disease, pheochromocytoma, Cushing's syndrome).
  • If the participant is on hypertensive medications, the antihypertensive has been changed in the 8 weeks prior to Screening (new drug or new dose).

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
770 participants (actual)

Study arms

  • Experimental
    Sotagliflozin 400 mg

    Following a 2-week run-in period, sotagliflozin 400 mg (milligrams) administered as two 200 mg tablets and one placebo capsule (identical to the empagliflozin capsule in appearance), once daily before the first meal of the day for up to 26 weeks.

    Drug: Sotagliflozin · Drug: Placebo

  • Active comparator
    Empagliflozin 25 mg

    Following a 2-week run-in period, placebo matching sotagliflozin administered as two tablets (identical to sotagliflozin in appearance) and one capsule of empagliflozin 25 mg, once daily before the first meal of the day for up to 26 weeks.

    Drug: Empagliflozin · Drug: Placebo

  • Placebo comparator
    Placebo

    Following a 2-week run-in period, placebo was given as two placebo tablets (identical to sotagliflozin) and one placebo capsule (identical to empagliflozin) once daily before the first meal of the day for up to 26 weeks.

    Drug: Placebo

Interventions

  • Sotagliflozin 400 mg was administered as two tablets, once daily before the first meal of the day.

    Also known as: SAR439954

  • Empagliflozin 25 mg capsule was administered, once daily before the first meal of the day.

  • DrugPlacebo

    Placebo was administered as two tablets (identical to sotagliflozin in appearance), once daily before the first meal of the day.

  • DrugPlacebo

    Placebo was administered as one capsule (identical to the empagliflozin capsule in appearance), once daily before the first meal of the day.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Hemoglobin A1c (HbA1c) % at Week 26

    An analysis of covariance (ANCOVA) model was used for the analysis.

    Time frame: Baseline, Week 26

Secondary outcomes

  1. Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 12 in Participants With Baseline SBP ≥ 130 mmHg

    An ANCOVA model was used for the analysis.

    Time frame: Baseline, Week 12

  2. Change From Baseline in 2-hour Postprandial Glucose (PPG) Following a Mixed Meal at Week 26

    An ANCOVA model was used for the analysis.

    Time frame: Baseline, Week 26

  3. Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26

    An ANCOVA model was used for the analysis.

    Time frame: Baseline, Week 26

  4. Change From Baseline in Body Weight at Week 26

    An ANCOVA model was used for the analysis.

    Time frame: Baseline, Week 26

  5. Change From Baseline in Sitting SBP at Week 12 for All Participants

    An ANCOVA model was used for the analysis.

    Time frame: Baseline, Week 12

  6. Percentage of Participants With HbA1c <6.5% at Week 26

    Time frame: Week 26

  7. Percentage of Participants With HbA1c <7.0% at Week 26

    Time frame: Week 26

07

Results

Posted May 11, 2021

Participant flow

Participants took part in the study at 160 investigative sites in Bulgaria, Canada, Czechia, France, Italy, Latvia, Mexico, Russian Federation, Slovakia, Spain, United Kingdom, and the United States from 27 November 2017 to 16 May 2019.

Participant flow — Overall Study
MilestoneSotagliflozin 400 mgEmpagliflozin 25 mgPlacebo
Started307309154
Completed293292147
Not completed14177
Withdrew: At the subject's own request11125
Withdrew: Adverse event121
Withdrew: Poor compliance to protocol100
Withdrew: Reason not specified130
Withdrew: Lost to follow-up001

Outcome measures

PrimaryChange From Baseline in Hemoglobin A1c (HbA1c) % at Week 26

An analysis of covariance (ANCOVA) model was used for the analysis.

Time frame:
Baseline, Week 26
Reported as:
Mean · percentage of HbA1c
Change From Baseline in Hemoglobin A1c (HbA1c) % at Week 26
percentage of HbA1cSotagliflozin 400 mgEmpagliflozin 25 mgPlacebo
Change From Baseline in Hemoglobin A1c (HbA1c) % at Week 26-0.7 ± 0.1-0.8 ± 0.1-0.3 ± 0.1
Statistical analysis
  • Sotagliflozin 400 mg vs Placebo · ANCOVA · p = < 0.0001 · Difference in least square (ls) means: -0.43 · 95% CI -0.62 to -0.25
  • Sotagliflozin 400 mg vs Empagliflozin 25 mg · ANCOVA · p = 0.145 · Difference in ls means: 0.12 · 95% CI -0.04 to 0.28
SecondaryChange From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 12 in Participants With Baseline SBP ≥ 130 mmHg

An ANCOVA model was used for the analysis.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · mmHg
Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 12 in Participants With Baseline SBP ≥ 130 mmHg
mmHgSotagliflozin 400 mgEmpagliflozin 25 mgPlacebo
Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 12 in Participants With Baseline SBP ≥ 130 mmHg-5.6 ± 1.3-6.7 ± 1.3-3.5 ± 1.5
Statistical analysis
  • Sotagliflozin 400 mg vs Placebo · ANCOVA · p = 0.1529 · Difference in ls means: -2.05 · 95% CI -4.87 to 0.76
  • Sotagliflozin 400 mg vs Empagliflozin 25 mg · ANCOVA · p = 0.3377 · Difference in ls means: 1.17 · 95% CI -1.21 to 3.55
SecondaryChange From Baseline in 2-hour Postprandial Glucose (PPG) Following a Mixed Meal at Week 26

An ANCOVA model was used for the analysis.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · millimole per liter (mmol/L)
Change From Baseline in 2-hour Postprandial Glucose (PPG) Following a Mixed Meal at Week 26
millimole per liter (mmol/L)Sotagliflozin 400 mgEmpagliflozin 25 mgPlacebo
Change From Baseline in 2-hour Postprandial Glucose (PPG) Following a Mixed Meal at Week 26-1.3 ± 0.2-1.2 ± 0.9-0.4 ± 0.2
Statistical analysis
  • Sotagliflozin 400 mg vs Placebo · ANCOVA · p = <0.0001 · Difference in ls means: -0.91 · 95% CI -1.33 to -0.5
  • Sotagliflozin 400 mg vs Empagliflozin 25 mg · ANCOVA · p = 0.8397 · Difference in ls means: -0.03 · 95% CI -0.37 to 0.3
SecondaryChange From Baseline in Fasting Plasma Glucose (FPG) at Week 26

An ANCOVA model was used for the analysis.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · mmol/L
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26
mmol/LSotagliflozin 400 mgEmpagliflozin 25 mgPlacebo
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26-1.3 ± 0.2-1.6 ± 0.2-0.5 ± 0.2
Statistical analysis
  • Sotagliflozin 400 mg vs Placebo · ANCOVA · p = 0.0005 · Difference in ls means: -0.8 · 95% CI -1.25 to -0.35
  • Sotagliflozin 400 mg vs Empagliflozin 25 mg · ANCOVA · p = 0.1339 · Difference in ls means: 0.3 · 95% CI -0.09 to 0.7
SecondaryChange From Baseline in Body Weight at Week 26

An ANCOVA model was used for the analysis.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · kilogram (kg)
Change From Baseline in Body Weight at Week 26
kilogram (kg)Sotagliflozin 400 mgEmpagliflozin 25 mgPlacebo
Change From Baseline in Body Weight at Week 26-2.7 ± 0.3-3.2 ± 0.3-0.5 ± 0.3
Statistical analysis
  • Sotagliflozin 400 mg vs Placebo · ANCOVA · p = <0.0001 · Difference in ls means: -2.25 · 95% CI -2.95 to -1.54
  • Sotagliflozin 400 mg vs Empagliflozin 25 mg · ANCOVA · p = 0.1407 · Difference in ls means: 0.51 · 95% CI -0.17 to 1.19
SecondaryChange From Baseline in Sitting SBP at Week 12 for All Participants

An ANCOVA model was used for the analysis.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · mmHg
Change From Baseline in Sitting SBP at Week 12 for All Participants
mmHgSotagliflozin 400 mgEmpagliflozin 25 mgPlacebo
Change From Baseline in Sitting SBP at Week 12 for All Participants-1.7 ± 0.8-2.8 ± 0.8-0.4 ± 1.0
Statistical analysis
  • Sotagliflozin 400 mg vs Placebo · ANCOVA · p = 0.0325 · Difference in ls means: -2.03 · 95% CI -3.89 to -0.17
  • Sotagliflozin 400 mg vs Empagliflozin 25 mg · ANCOVA · p = 0.1565 · Difference in ls means: 1.1 · 95% CI -0.42 to 2.63
SecondaryPercentage of Participants With HbA1c <6.5% at Week 26
Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With HbA1c <6.5% at Week 26
percentage of participantsSotagliflozin 400 mgEmpagliflozin 25 mgPlacebo
Percentage of Participants With HbA1c <6.5% at Week 2612.111.73.9
Statistical analysis
  • Sotagliflozin 400 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0048 · Percentage difference: 8.1 · 95% CI 3.36 to 12.89
SecondaryPercentage of Participants With HbA1c <7.0% at Week 26
Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With HbA1c <7.0% at Week 26
percentage of participantsSotagliflozin 400 mgEmpagliflozin 25 mgPlacebo
Percentage of Participants With HbA1c <7.0% at Week 2632.635.615.6
Statistical analysis
  • Sotagliflozin 400 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0001 · Percentage difference: 16.9 · 95% CI 9.26 to 24.52

Adverse events

Collected over First dose of study drug to last dose of study drug (up to 26 weeks) + 4 weeks (Approximately 30 weeks). Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sotagliflozin 400 mg0/307 (0%)10/307 (3.3%)58/307 (18.9%)
Empagliflozin 25 mg1/309 (0.3%)13/309 (4.2%)68/309 (22%)
Placebo0/154 (0%)9/154 (5.8%)39/154 (25.3%)
Most frequent serious events
Showing 10 of 37
Most frequent serious events
EventSotagliflozin 400 mgEmpagliflozin 25 mgPlacebo
PneumoniaInfections and infestations0/3070/3092/154
Hypertensive crisisVascular disorders0/3070/3091/154
Right ventricular failureCardiac disorders0/3070/3091/154
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/3070/3091/154
Pulmonary massRespiratory, thoracic and mediastinal disorders0/3070/3091/154
Cerebral ischaemiaNervous system disorders0/3070/3091/154
Ischaemic strokeNervous system disorders0/3070/3091/154
Intestinal obstructionGastrointestinal disorders0/3070/3091/154
Duodenal ulcerGastrointestinal disorders0/3070/3091/154
Skin ulcerSkin and subcutaneous tissue disorders0/3070/3091/154
Most frequent other events
Showing 10 of 12
Most frequent other events
EventSotagliflozin 400 mgEmpagliflozin 25 mgPlacebo
NasopharyngitisInfections and infestations12/30720/3095/154
HyperglycaemiaMetabolism and nutrition disorders6/3076/3099/154
Any HypoglycaemiaMetabolism and nutrition disorders2/3079/3097/154
HeadacheNervous system disorders7/3078/3096/154
ConstipationGastrointestinal disorders3/3075/3096/154
Urinary tract infectionInfections and infestations11/3078/3092/154
DiarrhoeaGastrointestinal disorders10/3078/3095/154
InfluenzaInfections and infestations5/3079/3095/154
Vulvovaginal mycotic infectionInfections and infestations5/30710/3091/154
Back painMusculoskeletal and connective tissue disorders6/3073/3094/154

Baseline characteristics

Intent-to-treat (ITT) population included all randomized participants.

Age, Continuous
Age, Continuous(years)Sotagliflozin 400 mgEmpagliflozin 25 mgPlaceboTotal
Mean58.9 ± 9.759.7 ± 9.659.8 ± 9.659.4 ± 9.6
Sex: Female, Male
Sex: Female, Male(Participants)Sotagliflozin 400 mgEmpagliflozin 25 mgPlaceboTotal
Female14115875374
Male16615179396
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Sotagliflozin 400 mgEmpagliflozin 25 mgPlaceboTotal
Hispanic or Latino566633155
Not Hispanic or Latino251243121615
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Sotagliflozin 400 mgEmpagliflozin 25 mgPlaceboTotal
American Indian or Alaska Native1821847
Asian1711432
Native Hawaiian or Other Pacific Islander2002
Black or African American1313531
White256257137650
More than one race0101
Unknown or Not Reported1607
Hemoglobin A1c (HbA1c)
Hemoglobin A1c (HbA1c)(percentage of HbA1c)Sotagliflozin 400 mgEmpagliflozin 25 mgPlaceboTotal
Mean8.23 ± 0.848.21 ± 0.938.21 ± 0.938.22 ± 0.90
Systolic Blood Pressure (SBP)
Systolic Blood Pressure (SBP)(millimeter of mercury (mmHg))Sotagliflozin 400 mgEmpagliflozin 25 mgPlaceboTotal
Mean134.55 ± 13.56131.64 ± 12.18133.19 ± 12.53133.11 ± 12.87
08

Study locations

160 sites
  • Investigational Site Number 8408035
    Birmingham, Alabama 35205, United States
  • Investigational Site Number 8408028
    Sheffield, Alabama 35660, United States
  • Investigational Site Number 8408047
    Hawaiian Gardens, California 90716, United States
  • Investigational Site Number 8408031
    Spring Valley, California 91978, United States
  • Investigational Site Number 8408067
    Van Nuys, California 91405, United States
  • Investigational Site Number 8408069
    Northglenn, Colorado 80234, United States
  • Investigational Site Number 8408009
    Miami, Florida 33183-4825, United States
  • Investigational Site Number 8408049
    Ocoee, Florida 34761, United States
  • Investigational Site Number 8408005
    Orlando, Florida 32810, United States
  • Investigational Site Number 8408040
    Orlando, Florida 32825, United States
  • Investigational Site Number 8408019
    Palmetto Bay, Florida 33157-5503, United States
  • Investigational Site Number 8408064
    Port Charlotte, Florida 33952, United States
  • Investigational Site Number 8408061
    Columbus, Georgia 31904, United States
  • Investigational Site Number 8408074
    Macon, Georgia 31210, United States
  • Investigational Site Number 8408079
    Savannah, Georgia 31406, United States
  • Investigational Site Number 8408059
    Statesboro, Georgia 30461-0845, United States
  • Investigational Site Number 8408051
    Blackfoot, Idaho 83221, United States
  • Investigational Site Number 8408033
    Elgin, Illinois 60124, United States
  • Investigational Site Number 8408003
    New Orleans, Louisiana 70124, United States
  • Investigational Site Number 8408002
    Rockville, Maryland 20852, United States
  • Investigational Site Number 8408044
    Fall River, Massachusetts 02721-3005, United States
  • Investigational Site Number 8408008
    Flint, Michigan 48532, United States
  • Investigational Site Number 8408027
    West Seneca, New York 14224, United States
  • Investigational Site Number 8408037
    Fayetteville, North Carolina 28314, United States
  • Investigational Site Number 8408053
    Greensboro, North Carolina 27408-7042, United States
  • Investigational Site Number 8408012
    Greensboro, North Carolina 27408, United States
  • Investigational Site Number 8408013
    Salisbury, North Carolina 28144-2742, United States
  • Investigational Site Number 8408045
    Oklahoma City, Oklahoma 73104-3252, United States
  • Investigational Site Number 8408068
    Warwick, Rhode Island 02888-3360, United States
  • Investigational Site Number 8408060
    Fort Mill, South Carolina 29707-4514, United States
  • Investigational Site Number 8408018
    Jefferson City, Tennessee 37760, United States
  • Investigational Site Number 8408010
    Knoxville, Tennessee 37912-4707, United States
  • Investigational Site Number 8408038
    Knoxville, Tennessee 37938, United States
  • Investigational Site Number 8408072
    Brownsville, Texas 78520-7512, United States
  • Investigational Site Number 8408056
    Dallas, Texas 75208, United States
  • Investigational Site Number 8408082
    Dallas, Texas 75230, United States
  • Investigational Site Number 8408052
    Dallas, Texas 75231, United States
  • Investigational Site Number 8408001
    Houston, Texas 77004, United States
  • Investigational Site Number 8408032
    Houston, Texas 77004, United States
  • Investigational Site Number 8408016
    Houston, Texas 77040, United States
  • Investigational Site Number 8408017
    Houston, Texas 77058, United States
  • Investigational Site Number 8408036
    Houston, Texas 77061, United States
  • Investigational Site Number 8408022
    Houston, Texas 77099, United States
  • Investigational Site Number 8408029
    Katy, Texas 77450, United States
  • Investigational Site Number 8408054
    McAllen, Texas 78504, United States
  • Investigational Site Number 8408039
    Mesquite, Texas 75149, United States
  • Investigational Site Number 8408042
    Plano, Texas 75024, United States
  • Investigational Site Number 8408011
    San Antonio, Texas 78229-3818, United States
  • Investigational Site Number 8408041
    Schertz, Texas 78154, United States
  • Investigational Site Number 8408007
    Bountiful, Utah 84010-7717, United States
  • Investigational Site Number 8408026
    Holladay, Utah 84117, United States
  • Investigational Site Number 8408006
    Burke, Virginia 22015, United States
  • Investigational Site Number 8408004
    Manassas, Virginia 20110, United States
  • Investigational Site Number 1008011
    Gabrovo, 5300, Bulgaria
  • Investigational Site Number 1008006
    Plovdiv, 4000, Bulgaria
  • Investigational Site Number 1008001
    Plovdiv, 4002, Bulgaria
  • Investigational Site Number 1008005
    Ruse, 7002, Bulgaria
  • Investigational Site Number 1008007
    Ruse, 7003, Bulgaria
  • Investigational Site Number 1008002
    Smolyan, 4700, Bulgaria
  • Investigational Site Number 1008008
    Sofia, 1606, Bulgaria
  • Investigational Site Number 1008012
    Sofia, 1632, Bulgaria
  • Investigational Site Number 1008003
    Stara Zagora, 6000, Bulgaria
  • Investigational Site Number 1008010
    Stara Zagora, 6000, Bulgaria
  • Investigational Site Number 1008004
    Varna, 9000, Bulgaria
  • Investigational Site Number 1248001
    Brampton, L6T 0G1, Canada
  • Investigational Site Number 1248007
    Burlington, L7M 4Y1, Canada
  • Investigational Site Number 1248003
    Newmarket, L3Y 5G8, Canada
  • Investigational Site Number 1248010
    Quebec, G1N 4V3, Canada
  • Investigational Site Number 1248009
    Sherbrooke, J1L 0H8, Canada
  • Investigational Site Number 1248002
    Thornhill, L4J 1W3, Canada
  • Investigational Site Number 1248004
    Toronto, M3M 3E5, Canada
  • Investigational Site Number 1248011
    Toronto, M9W 4L6, Canada
  • Investigational Site Number 1248005
    Vancouver, V5Y 3W2, Canada
  • Investigational Site Number 1248008
    Victoriaville, G6P 6P6, Canada
  • Investigational Site Number 2038007
    Brandys, 250 01, Czechia
  • Investigational Site Number 2038003
    Havirov, 736 01, Czechia
  • Investigational Site Number 2038004
    Krnov, 794 01, Czechia
  • Investigational Site Number 2038011
    Ostrava, 710 00, Czechia
  • Investigational Site Number 2038006
    Pardubice, 530 02, Czechia
  • Investigational Site Number 2038010
    Plzen, 363 01, Czechia
  • Investigational Site Number 2038005
    Prague, 18100, Czechia
  • Investigational Site Number 2038001
    Praha 10 - Uhrineves, 104 00, Czechia
  • Investigational Site Number 2038009
    Praha 1, 110 00, Czechia
  • Investigational Site Number 2038013
    Praha 2, 128 00, Czechia
  • Investigational Site Number 2038002
    Praha 4, 149 00, Czechia
  • Investigational Site Number 2038008
    Praha 9, 190 14, Czechia
  • Investigational Site Number 2508005
    Corbeil-Essonnes, 91106, France
  • Investigational Site Number 2508006
    La Roche Sur Yon, 85925, France
  • Investigational Site Number 2508007
    La Tronche, 38700, France
  • Investigational Site Number 2508003
    Mulhouse, 68100, France
  • Investigational Site Number 2508002
    Nantes Cedex 1, 44093, France
  • Investigational Site Number 2508001
    Paris, 75018, France
  • Investigational Site Number 2508004
    Saint-Mandé, 94160, France
  • Investigational Site Number 3808010
    Catania, 95122, Italy
  • Investigational Site Number 3808003
    Catania, 95123, Italy
  • Investigational Site Number 3808002
    Chieti, 66100, Italy
  • Investigational Site Number 3808004
    Milano, 20122, Italy
  • Investigational Site Number 3808005
    Milano, 20132, Italy
  • Investigational Site Number 3808009
    Pavia, 27100, Italy
  • Investigational Site Number 3808008
    Roma, 00133, Italy

Showing the first 100 of 160 sites across 12 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available Sanofi continues to protect the privacy of the participants in clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in May 2019, 17 months.

Results were first posted in May 2021, 1 year 11 months after primary completion. A results delay was requested in Apr 2020.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 17 months is below that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2017
First posted
Nov 22, 2017
StartActual
Nov 27, 2017
Primary completionActual
May 16, 2019
CompletionActual
May 16, 2019
Results delay requested
Apr 28, 2020
Results first posted
May 11, 2021
Last update
May 11, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03351478
Collaborators
Sanofi
Responsible party
Sponsor
First posted
Nov 22, 2017
Start date
Nov 27, 2017
Primary completion
May 16, 2019
Completion
May 16, 2019
Results posted
May 11, 2021
Last update
May 11, 2021

Study contacts

Suman Wason
study director · Lexicon Pharmaceuticals, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sotagliflozin

Start the discussion